Unless you’ve been hiding under a rock somewhere, you’re probably aware that the marijuana industry is booming. With more than half the U.S. legalizing medical marijuana, several legalizing recreational marijuana, and Canada recently making recreational marijuana legal nationwide, demand is greater than ever. Promising marijuana-based drugs could be on the market in the near future.
There are several reasons to think that marijuana stocks still have plenty of upward potentials. But what are some marijuana stocks to consider for investors who have yet to jump on the bandwagon? Here’s why Scotts Miracle-Gro Company (NYSE: SMG), GW Pharmaceuticals (NASDAQ: GWPH), and Canopy Growth Corporation (NASDAQOTH: TWMJF) are three marijuana stocks you could buy if you’ve never bought a marijuana stock before.
These Marijuana Stocks Be The Future Of The Industry
Scotts Miracle-Gro doesn’t cultivate marijuana. It doesn’t develop marijuana-based drugs. Technically speaking, Scotts Miracle-Gro isn’t a marijuana stock. But it might as well be.
Much of Scotts’ focus and fortune is tied directly to the marijuana industry. Scotts Miracle-Gro provides key supplies for marijuana growers, including fertilizers, hydroponics, and lighting. The company’s business currently skews toward small recreational growers, but Scotts also has a solid presence among professional growers and a strategy to build its relationships with larger players.
Of course, not all of Scotts Miracle-Gro’s business is connected to marijuana; that’s what makes it a compelling choice for an investor who is new to investing in marijuana stocks. Buying Scotts Miracle-Gro shares allows you to participate in the growth of the marijuana industry, but with more stability than you would get buying a micro-cap marijuana stock.
GW Pharmaceuticals is, for now at least, is one of the biggest biotech specializing in the development of marijuana-based drugs. The company has one cannabis product on the market already in 16 countries outside of the U.S. — the muscular-sclerosis spasticity drug Sativex. Yet, the greatest opportunity for GW Pharmaceuticals lies in a cannabinoid drug that hasn’t been approved yet.
The biotech reported positive results last year from late-stage clinical studies evaluating cannabidiol drug Epidiolex in treating Dravet syndrome and Lennox-Gastaut syndrome (LGS). GW Pharmaceuticals is on track to submit Epidiolex for U.S. regulatory approval soon and for European approval later this year.
Canopy Growth Corporation
With Canada recently passing legal marijuana Canopy Growth Corporation could be a good way for investors to profit from the anticipated growth in the Canadian marijuana market. Canopy Growth already ranks as one of the largest providers of medical marijuana in the country.
Just how big could the Canadian marijuana market be? Professional services firm Deloitte released a report that projected the retail marijuana market in Canada could grow to $8.7 billion annually. To put that into perspective, Canopy Growth’s revenue last year was only around $30 million.
Canopy Growth should be in a great place to become an authorized provider of recreational marijuana. The company has already made several acquisitions. It wouldn’t be surprising to see Canopy Growth buy smaller operations to expand its presence in Canada and other countries.